Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone implant adjunct to Lucentis in neovascular age-related macular degeneration
2007-004416-31Phase 2Completed
- Sponsor
- Allergan
- Start
- Nov 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of dexamethasone and ranibizumab in age-related macular degeneration (AMD) and Subretinal neovascularization (2 arms), sponsored by Allergan. Primary endpoint: Time from second Lucentis injection to eligibility for third Lucentis injection. Started Nov 2007; status: completed.
02
Drugs
dexamethasoneranibizumab
03
Conditions
age-related macular degeneration (AMD)Subretinal neovascularization
Beyond the preview
Go deeper on 2007-004416-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004416-31.